VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | Overcoming resistance to PARP inhibition in ovarian cancer

Anniina Färkkilä, MD, PhD, Helsinki University, Helsinki, Finland, describes strategies to reduce the incidence of PARP resistance in patients with ovarian cancer, which currently is an unmet need. Novel combinations and earlier interventions with the aim of preventing resistance are currently under investigation. Research assessing BRCA reversion mutations and vaccinations are additionally underway. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter